Arvinas Q2 2026 Earnings Report

Arvinas EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.24
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Arvinas Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $60.71 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Arvinas Announcement Details

• Quarter: Q2 2026
• Date: 8/5/2026
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 4, 2026
• Conference Call Time: 8:00AM ET

Arvinas (NASDAQ:ARVN) (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers. ARV-110 (bavdegalutamide) is being evaluated for the treatment of metastatic castration-resistant prostate cancer, while ARV-471 (voredabolu) is in development for ER+/HER2- breast cancer. Both programs have shown favorable pharmacokinetic profiles in early-phase trials and reflect Arvinas’s strategy of advancing a focused pipeline of next-generation small molecules designed to degrade pathogenic proteins.

Since its founding in 2013 and incorporation in New Haven, Connecticut, Arvinas has established collaborative partnerships with leading pharmaceutical companies to expand the reach of its PROTAC platform. Agreements with Pfizer and Roche, among others, provide access to complementary expertise in oncology and other therapeutic areas. The company conducts research and development in the United States and maintains relationships with regulatory authorities in North America and Europe as it pursues global clinical development.

Arvinas is led by President and Chief Executive Officer Robert A. Ross, who joined the company in 2022 following a tenure at a major pharmaceutical association. Under his leadership, the company continues to advance its pipeline while building a broader platform for targeted protein degradation. Arvinas remains committed to translating its scientific innovations into transformative therapies for patients with unmet medical needs.